More than 600 fintech professionals and regulators will gather in Riga to discuss MiCA, payments, investment and the future of financial services.
On October 15, more than 600 fintech professionals, private investors and European Union regulators will gather in Riga for UN:BLOCK Fintech, a one-day conference exploring the issues reshaping financial services.
AAWE founder Tom Belt argues that what businesses call loyalty is usually habit or inertia, and that growth comes from the experience customers actually get.
Loyalty schemes, cards, discounts and rewards all rest on the assumption that loyalty exists and can be bought.
LemFi co-founder and CEO Ridwan Olalere argues that fintech must let migrants carry their credit history and financial identity with them across borders.
More than 300 million people now live outside their country of birth, and for many of them a credit history does not survive the move. The founder of one cross-border finance platform argues that this is the gap fintech has so far left open.
Descope's Cross-App Access standard replaces static API keys with short-lived tokens, letting enterprises govern AI agents via existing identity providers.
Descope's Cross-App Access standard replaces static API keys with short-lived tokens, letting enterprises govern AI agents via existing identity providers.
The Singapore-based well logging company completed a SPAC merger to reach public markets, citing geothermal and carbon storage among its target applications.
The French biomass-to-fuels developer will deliver thermolysis equipment to Bécancour's INCAD project, Quebec's first hub targeting RNG, biochar and SAF.
Oryzon Genomics has received EMA authorisation to begin a Phase IIa study of vafidemstat in Phelan-McDermid Syndrome, a rare autism-linked genetic disorder with
Castrol has launched CORE, an end-to-end thermal management offer combining design, cooling technology and lifecycle services for data centre operators.
Belite Bio will present topline Phase 3 results for tinlarebant in adolescent Stargardt disease at Euretina in Vienna, ahead of a February 2027 FDA PDUFA